Molecular basis of mucopolysaccharidosis type II (Hunter syndrome): first review and classification of published IDS gene variants

被引:0
|
作者
Alessandra Zanetti [1 ]
Francesca D’Avanzo [2 ]
Rosella Tomanin [1 ]
机构
[1] Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women’s and Children’s Health, University of Padova, Padova
[2] Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova
关键词
Enzyme replacement therapy; Hunter syndrome; IDS; IDS variants; IDSP1; Iduronate; 2-sulfatase; Lysosomal storage disorder; MPS II; Mucopolysaccharidosis type II; Recombination; Variants classification;
D O I
10.1186/s40246-024-00701-w
中图分类号
学科分类号
摘要
Purpose: Mucopolysaccharidosis type II (MPS II) is a rare X-linked lysosomal storage disorder caused by genetic alterations in the iduronate 2-sulfatase (IDS) gene. A wide range of variants has been reported for different countries and ethnic groups. We collected, analyzed and uniformly summarized all published IDS gene variants reported in literature up to June 2023, here providing the first worldwide review and classification. Methods: Data was obtained from a literature search, conducted in PubMed and Google. All data was analyzed to define the most common alleles, geographic distribution and genotype-phenotype correlation. Moreover, point variants were classified according to their pathogenicity, based on the ACMG guidelines. Results: Several types of variants have been described in the IDS gene, including intrachromosomal homologous recombination occurring between the homologous regions of IDS gene and its pseudogene IDSP1. Overall, we collected 2852 individuals from 2798 families, including 24 female patients. Most families carried missense variants, followed by large deletions-insertions and complex rearrangements, small frameshift deletions/insertions and nonsense variants. Based on ACMG guidelines, 62.9% of the 779 point variants were classified as “pathogenic”, 35.4% as “likely pathogenic”, and the remaining 13 variants as having “uncertain significance”. Conclusion: Data from this study confirmed that MPS II is a genetically very heterogeneous disorder, making genotype-phenotype correlation very challenging and in most cases merely unfeasible. Mutation updates are essential for the correct molecular diagnosis, genetic counseling, prenatal and preimplantation diagnosis, and disease management. © The Author(s) 2024.
引用
收藏
相关论文
共 50 条
  • [31] Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities
    Zapolnik, Pawel
    Pyrkosz, Antoni
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [32] Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome)
    Amartino, H.
    Ceci, R.
    Masllorens, F.
    Arberas, A. Gal D. C.
    Bay, L.
    Ilari, R.
    Dipierri, J.
    Specola, N.
    Cabrera, A.
    Rozenfeld, P.
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2014, 1 : 401 - 406
  • [33] Association between brain structural anomalies, electroencephalogram and history of seizures in Mucopolysaccharidosis type II (Hunter syndrome)
    Ernesto Jimenez-Arredondo, Ramon
    Leticia Brambila-Tapia, Aniel Jessica
    Miguel Mercado-Silva, Francisco
    Ortiz-Aranda, Martha
    Benites-Godinez, Veronica
    Olmos-Garcia-de-ALBA, Graciela
    Eduardo Figuera, Luis
    NEUROLOGICAL SCIENCES, 2017, 38 (03) : 445 - 450
  • [34] Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome)
    Gusarova, Valentina D.
    Smolov, Maxim A.
    Lyagoskin, Ivan V.
    Degterev, Maksim B.
    Rechetnik, Elizaveta V.
    Rodionov, Alexander V.
    Pantyushenko, Marina S.
    Shukurov, Rahim R.
    BIODRUGS, 2023, 37 (03) : 375 - 395
  • [35] The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
    Mireia Raluy-Callado
    Wen-Hung Chen
    David A H Whiteman
    Juanzhi Fang
    Ingela Wiklund
    Orphanet Journal of Rare Diseases, 8
  • [36] Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
    da Silva, Edina M. K.
    Louzada Strufaldi, Maria Wany
    Andriolo, Regis B.
    Silva, Laercio A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (11):
  • [37] Intrathecal baclofen in mucopolysaccharidosis type II (Hunter syndrome): case report
    Horn, Frantisek
    Petrik, Michal
    Dubravova, Dana
    Hornova, Jarmila
    Brennerova, Katrina
    Bzduch, Vladimir
    CHILDS NERVOUS SYSTEM, 2018, 34 (11) : 2325 - 2327
  • [38] Intrathecal baclofen in mucopolysaccharidosis type II (Hunter syndrome): case report
    František Horn
    Michal Petrík
    Dana Dúbravová
    Jarmila Hornová
    Katrína Brennerová
    Vladimír Bzduch
    Child's Nervous System, 2018, 34 : 2325 - 2327
  • [39] HUNTER SYNDROME (TYPE II MUCOPOLYSACCHARIDOSIS). KEYS FOR ITS RECOGNITION AND DIAGNOSIS
    Andres, A. G. Andres
    BOLETIN DE PEDIATRIA, 2024, 64 (267):
  • [40] Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)
    da Silva, Edina M. K.
    Strufaldi, Maria Wany Louzada
    Andriolo, Regis B.
    Silva, Laercio A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (01):